Currently holds positions in aTyr Pharma Inc and Fate Therapeutics Inc
Position | Company | Period |
---|---|---|
Director | aTyr Pharma Inc | Nov. 1, 2017 - |
Vice Chairman of the Board | Fate Therapeutics Inc | Jan. 1, 2017 - |
Independent Director | Editas Medicine Inc | Jan. 1, 2016 - March 27, 2018 |
Chief Executive Officer, Director | aTyr Pharma Inc | Dec. 1, 2015 - Nov. 1, 2017 |
Vice Chairman of the Board | Fate Therapeutics Inc | None - |
Chief Executive Officer and Executive Chairman, Board of Directors | aTyr Pharma Inc | Sept. 1, 2011 - Dec. 1, 2015 |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2023-01-13 | 2023-01-13 |
Fate Therapeutics Inc
(FATE)
|
B Purchase |
36,631
+14.9%
5.43198,906 USD |
36,631 +14.9% | 5.43 | 198,906 USD | |
2023-01-13 | 2023-01-11 |
Fate Therapeutics Inc
(FATE)
|
B Purchase |
88,048
+55.7%
5.67499,232 USD |
88,048 +55.7% | 5.67 | 499,232 USD | |
2022-06-06 | 2022-06-03 |
Fate Therapeutics Inc
(FATE)
|
S Sale |
1,364
-0.9%
22.7931,086 USD |
1,364 -0.9% | 22.79 | 31,086 USD | |
2022-03-11 | 2022-03-10 |
Fate Therapeutics Inc
(FATE)
|
PS Planned sale |
12,069
-7.0%
35.48428,208 USD |
12,069 -7.0% | 35.48 | 428,208 USD | |
2022-03-11 | 2022-03-10 |
Fate Therapeutics Inc
(FATE)
|
PS Planned sale |
19,493
-10.2%
34.73676,992 USD |
19,493 -10.2% | 34.73 | 676,992 USD |